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Available online 31 May 2017Capripoxviruses (CaPVs) have been shown to be ideal viral vectors for the development of recombinantmultiva-
lent vaccines to enable delivery of immunogenic genes from ruminant pathogens. So far, the viral thymidine
kinase (TK) gene is the only gene used to generate recombinants. A putative non-essential gene encoding
a G-protein-coupled chemokine receptor subfamily homologue (GPCR) was targeted as an additional insertion
site. Peste des petits ruminants (PPR) was chosen as a disease model. A new recombinant CaPV expressing the
viral attachment hemagglutinin (H) of the PPR virus (PPRV) in the GPCR insertion site (rKS1-HPPR-GPCR) was
generated in the backbone North African isolate KS1 strain of lumpy skin disease virus (LSDV). Comparison
with the recombinant CaPV expressing theH of PPRV in the TK gene (rKS1-HPPR-TK) shown to induce protection
against both PPR and LSD in both sheep and goats was assessed. The suitability of the GPCR gene to be a putative
additional insertion site in the CaPV genome is evaluated and discussed.
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Goats1. Introduction
Sheep pox virus (SPPV) and goat pox virus (GTPV), along with
lumpy skin disease virus (LSDV), a pathogen speciﬁc to cattle, aremem-
bers of the viral genus Capripoxviruswhich cause primary viral diseases
that have a signiﬁcant impact on the livestock industry.
Capripoxviruses (CaPVs) have been shown to be ideal viral vectors for
the development of recombinant multivalent vaccines to enable delivery
of immunogenic genes from ruminant pathogens which share the same
geographical distribution (Africa, the Middle East and Asia) (Diallo et al.
2002). They are thermo-resistant and their genome enables insertion of
a large recombinant DNA sequence. The live attenuated strain of LSDV,
Kenya Sheep 1 (KS1) (Kitching et al. 1987) and the South African vaccine
strain of LSDV have been used as vaccine vectors against livestock dis-
eases such as rinderpest, peste des petits ruminants (PPR), bluetongue
and Rift Valley fever (Boshra et al. 2013; Diallo et al. 2002; Diallo, 2003;
Wallace and Viljoen, 2005; Perrin et al. 2007; Soi et al. 2010). The strategy
to generate pox virus recombinants is based on the homologous recombi-
nation between a speciﬁc gene of the pox virus genome and the ﬂanking
regions of the same speciﬁc gene encompassing both the transgene to be
expressed and a dominant selectable marker. The viral thymidine kinaseR1309, 2, Rue Maxime Rivière,
re-Sossah).(TK) gene, which was found to be non-essential for normal growth, was
ﬁrst used to generate recombinants in the Vaccinia virus and later in the
CaPVs (Diallo et al. 2002). A challenge facing the development of a suc-
cessful vector is generating several insertion sites for multi-gene expres-
sion that do not impair replication of the virus. A putative non-essential
gene encoding a G-protein-coupled chemokine receptor subfamily
homologue (GPCR) was targeted for homologous recombination using
the backbone North African isolate KS1 strain of LSDV (Cao et al. 1995;
Le Goff et al. 2009).
Peste des petits ruminants (PPR) is one of the most contagious dis-
eases affecting small ruminants. A new recombinant CaPV expressing
the viral attachment hemagglutinin (H) of the PPR virus (PPRV) in the
GPCR insertion site (rKS1-HPPR-GPCR) was generated. Comparison
with the recombinant CaPV expressing the H of PPRV in the TK gene
(rKS1-HPPR-TK) shown to induce protection against both PPR and
LSD in both sheep and goats (Caufour et al. 2014) was assessed. The
aim of this study was to evaluate the suitability of the GPCR gene as a
putative additional insertion site in the CaPV genome.
2. Materials and methods
2.1. Cells and viruses
The ovine lamb testis cell line OA3.Ts (ATCC CRL-6546) and Vero cells
(ATCC CCL681) were used to propagate CaPV and PPRV respectively. All
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attenuated CaPV vaccine strain KS1 (Kenya KS-GP 0240 strain (Kitching
et al. 1987), attenuated PPRV vaccine strain Nigeria 75/1 (Diallo, 2003),
CaPV (KS1 based) containing the PPRV-H gene into the TK insertion site
(Diallo et al. 2002), CaPV (KS1 based) containing the PPRV-H gene into
the GPCR insertion site (this study) and the virulent ﬁeld strains of
GTPV Yemen and PPRV India 94/1.
2.2. Generation of the recombinant capripoxvirus rKS1-HPPR-GPCR
The GPCR ﬂanking regions GPCR1 and GPCR2 of the KSGP 0240
(KS1) strain were inserted by enzymatic digestion at the sites KpnI/SﬁI
and BstXI respectively in the previously described plasmid pFPJ2
(Berhe et al. 2003). The Escherichia coli xanthine-guanine
phosphoribosyltransferase gene (Ecogpt) was used as a dominant se-
lectable marker to isolate the recombinant. The Ecogpt-p7.5-p7.5 PPR
F gene cassette was replaced by the Ecogpt-PS-PS-PPR H gene cassette
thereby allowing the H-PPR gene and the Ecogpt to be placed under
the control of the vaccinia virus early/late synthetic promoter (a gener-
ous gift fromDr. Drillien, University of Strasbourg, France). To check the
insertion of the inserted gene in the cassette, speciﬁc PCR based on the
GPCR ﬂanking regions and the inserted gene H-PPRV have been per-
formed. Final constructions were checked and compared in transient
expression assays consisting of the transfection of lamb testis cells
(OA3Ts) and infection with the capripoxvirus vaccine strain KS-1.
Validated constructions were further used to generate recombinant
KS1 capripoxviruses by infection-transfection of OA3Ts as described
previously (Perrin et al. 2007). The purity of the recombinant virus
was conﬁrmed by the absence of detectable parental virus using a PCR
performed directly on DNA extracted from the viral supernatant
targeting the GPCR gene.
2.3. Immunization and experimental challenge
An animal experiment was carried out on four groups of three
Guinea Dwarf goats each, injected subcutaneously with a dose ofFig. 1. Experimental design of immunizations and challenges. Groups 1 and 2 were ﬁrst imm
animal) respectively. Groups 3 and 4 considered as challenge PPRV and CaPV control gro
supernatant respectively. Three weeks later, all groups were challenged SC with the virulent
strain PPRV India 94 (103,8/animal) two weeks later. The timing of immunizations and challen103 TCID50/animal (50% Tissue culture infective dose) with either
rKS1-HPPR-TK, rKS1-HPPR-GPCR, the attenuated CaPV KS1 vaccine
(PPRV challenge positive control group) or Vero cell supernatant
(mock, CaPV challenge positive control group). To limit the number
of animals in the experiment, only two animals were included in
the mock group. The virulent Yemen GPV and the India 94 PPRV
strains were sequentially used as challenge in all groups at day 21 and
day 35 post immunization respectively at a dose of 103 TCID50/animal
(Fig. 1).
All experimental procedures were in accordance with ethical stan-
dards. The study was approved by the Ethics Committee for Animal Ex-
perimentation of CIRAD, Montpellier, France (permit F 34-172-15).
Serum samples collected prior to immunization and weekly over an 8-
week period post immunization were analyzed for H-PPRV antibodies
by ELISA (Libeau et al., 1995) and conﬁrmed by VNT (OIE 2012;
Rossiter et al. 1985).
All the animals were observed daily for the appearance of clinical
signs which were used collectively to give a ﬁnal severity score for
each animal: overall behavior (good, 1 pt; apathy, 1 pt; prostration, 2
pts; recumbence, 3 pts), clinical signs (rectal temperature, 39 °C or
above, 1 pt; cutaneous lesions at the site of injection, 1 pt; other
extensive cutaneous lesions, 2 pts; respiratory problems [mild nasal
discharge, 1 pt; severe nasal discharge, 2 pts; mild ocular discharge, 1
pt; severe ocular discharge, 2 pts, cough, 1 pt]; digestive problems
[mild stomatitis (with oral lesions), 1 pt; necrotizing stomatitis (with
oral lesions), 3 pts; diarrhea, 3 pts]; death, 20 pts. The score given for
one animal in Fig. 2 corresponds to the total number of points accumu-
lated during the experiment (from the day of the challenge until the day
of euthanasia) divided by the number of days the animal presented
clinical signs.3. Results and discussion
The virulent Yemen GPV and the India 94 PPRV strains sequentially
used as challenge in all four groups of goats produced the expected se-
vere clinical signs in the respective control group. The two animals inunized subcutaneously (SC) with rKS1-HPPR TK (103/animal) or rKS1-HPPR GPCR (103/
ups were immunized with attenuated CaPV KS1 vaccine (103/animal) and Vero cells
ﬁeld Yemen goatpox strain (102,8/animal) followed by a SC PPR challenge with the ﬁeld
ges are indicated by arrows.
Fig. 2. Scores of clinical signs. Clinical signs including mortality were scored for each animal in the experiment. * means death.
Table 1
PPRV antibody detection in goats after recombinant CaPV rKS1-HPPR TK or rKS1-HPPR
GPCR immunizations followed by CaPV and PPR challenges.
Goat
Id
Group (inoculum) PPRV antibody detection (ELISA/VNT titers)
Preinoculation 4 dppc 7 dppc 14 dppc
90 1 (rKS1-HPPT TK) Neg/Neg Pos/60 Pos/60 Pos/60
94 1 (rKS1-HPPT TK) Neg/Neg Neg/Neg Neg/Neg Neg/Neg
100 1 (rKS1-HPPT TK) Neg/Neg Pos/15 Pos/30 Pos/480
85 2 (rKS1-HPPR GPCR) Neg/Neg Neg/15 Pos/240 Pos/480
95 2 (rKS1-HPPR GPCR) Neg/Neg NA NA NA
XX4 2 (rKS1-HPPR GPCR) Neg/Neg Pos/100 Pos/240 Pos/200
88 3 (attenuated CaPV KS1
vaccine)
Neg/Neg Neg/Neg Pos/100 Pos/480
92 3 (attenuated CaPV KS1
vaccine)
Neg/Neg NA NA NA
107 3 (attenuated CaPV KS1
vaccine)
Neg/Neg Neg/Neg Neg/Neg
86 4 (mock) Neg/Neg NA NA NA
1090 4 (mock) Neg/Neg NA NA NA
Id stands for identiﬁcation; dppc, days post PPR challenge, PPRV for Peste des Petits Rumi-
nants Virus; VNT for Virus Neutralisation Test; ELISA for Enzyme Linked ImmunoSorbent
Assay); NA, not available; Neg, no antibody detected; Pos, positive antibody detection.
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group had severe clinical signs with a score of up to 13 points (Fig. 2)
and the two animals of the mock group considered as the CaPV
challenge control group died.
After the CaPV challenge, one animal out of three in each of the rKS1-
HPPR-GPCR, attenuated CaPV KS1 vaccine groups developed severe
clinical signs or died at days 10 and 11 post challenge respectively,
attesting to partial protection against CaPV in the tested group (Fig. 2).
The CaPV KS1 vaccine has proved for many years its protective effect
in experimental conditions and in mass vaccination programs in the
ﬁeld (Kitching et al. 1987). Finding clinical signs in two of the CaPV
vaccinated groups (including the CaPV KS1 vaccine group) while the
two animals of the control group died suggest a possible overdosage
of the viral challenge inoculum.
After the PPRV challenge, in the rKS1-HPPR-TK group, one animal
out of three (Goat ID Number 94) died at day 12 post challenge without
developing any speciﬁc anti-PPRV antibodies,whereas all the animals in
the group rKS1-HPPR-GPCR developed speciﬁc anti-PPRV antibodies
without any clinical signs, attesting to full protection of the animals
against PPR (Table 1, Fig. 2). The unexpected death of that particular
goat in the rKS1-HPPR-TK group remains unexplained.
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a putative insertion site resulted in highly encouraging data and paves
the way to proceed from a CaPV homologous recombination strategy
to amulti-pathogen delivery approach. Further experimentswith larger
groups of animals are needed to conﬁrm these ﬁrst experimental re-
sults. The generation of CaPV-based recombinant vaccines containing
immunogenic genes of pathogens of interestwhich affect the same geo-
graphical zone is the next step. The development and experimental and
ﬁeld validation of such vaccines will offer decision makers the opportu-
nity to better control diseases.
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